Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 6/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CA4 | P22748 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11582128 | 0.78 | ALDH1A1 (0.52) | KCNH2HTR2AALDH1A1HSD17B10TDP1 | |
| SCHEMBL344823 | 0.75 | CES1 (0.46) | CES1KCNH2ALDH1A1HSD17B10FAAH | |
| SCHEMBL6804128 | 0.75 | CES1 (0.36) | CES1KCNH2KCNJ1FAAHNCEH1 | |
| SCHEMBL29086344 | 0.74 | CYP1B1 (0.32) | CES1FAAHNCEH1 | |
| SCHEMBL30443790 | 0.73 | TAAR1 (0.47) | — | |
| SCHEMBL11583152 | 0.71 | ALDH1A1 (0.62) | KCNH2ALDH1A1HSD17B10TDP1CA2 | |
| Formamide SCHEMBL28728347 | 0.71 | CES1 (0.43) | CES1HSD17B10CA2CA1FAAH | |
| SCHEMBL4469516 | 0.70 | CA2 (0.44) | KCNH2HTR2AALDH1A1HSD17B10TDP1 | |
| SCHEMBL14610271 | 0.70 | GFER (0.58) | ALDH1A1TDP1CA2CA1CA4 | |
| SCHEMBL1951129 | 0.69 | LTA4H (0.49) | KCNH2ALDH1A1HSD17B10TDP1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170369483-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060111351-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2005112925-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050137193-A1 | Aryl sulfonamides | CHEMOCENTREYX | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137193-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | CES1 347/4885KCNH2 3891/4885HTR2A 1701/4885 |
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | CES1 347/4885KCNH2 3891/4885HTR2A 1701/4885 |
| US-20120014997-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CES1 347/4885KCNH2 3891/4885HTR2A 1701/4885 |
| US-20060111351-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | CES1 347/4885KCNH2 3891/4885HTR2A 1701/4885 |
| US-20170369483-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CES1 347/4885KCNH2 3891/4885HTR2A 1701/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CES1 347/4885KCNH2 3891/4885HTR2A 1701/4885 |
| US-20090163498-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | CES1 347/4885KCNH2 3891/4885HTR2A 1701/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CES1 347/4885KCNH2 3891/4885HTR2A 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.